SAS (Scandinavian Airlines) Improves Customer Service and Cuts Costs with Scandit’s Barcode Scanning on Smartphones
9.12.2019 10:00:00 EET | Business Wire | Press release
Scandit, the leading enterprise technology platform for mobile computer vision and augmented reality (AR), today announced that SAS (Scandinavian Airlines System) has integrated its powerful scanning software into their new Ground Handling App for smartphones, to replace expensive built-in scanners and upgrade critical ground workflows.
The mobile app (developed by Stockholm-based Objective Solutions) brings new efficiency and cost savings to workflows using mobile scanning of boarding passes, passports, meal vouchers and baggage tags. SAS has deployed the Scandit-powered app to their three Scandinavian airport hubs: Stockholm Arlanda, Oslo Gardermoen, and Copenhagen Kastrup. A detailed case study about the integration is now available.
SAS carries more than 30 million passengers annually to 120 destinations on over 170 aircraft and is widely recognized as a pioneer in digital innovation for the air travel industry. The Ground Handling App is part of a global, digital infrastructure initiative to streamline and improve key operations and improve the travelling experience for their growing volume of passengers. In the first deployment, SAS employees were equipped with 700 Galaxy A8 devices, with further rollouts planned across SAS’ global operations.
The Scandit software was easily integrated into the SAS IT ecosystem. Customer-facing SAS employees use the mobile app from anywhere in the airport, for example at the boarding gate where agents are no longer tied to gate podiums. Passengers are benefiting from a faster, more personalized service and SAS has reduced costs compared to the dedicated scanners and infrastructure. Booking changes can also be done seamlessly with the mobile app and baggage handlers use it to record and track baggage.
“We chose Scandit for its quality and flexibility,” said Fredrik Buxfeldt, Head of Digital Operations IT at SAS. “In addition to barcode scanning and OCR (optical character recognition) in mobile apps, Scandit also enables barcode scanning in websites, so our employees can also use mobile scanning from a browser if they don’t have the mobile app loaded.”
“SAS has reaped the benefits of modernizing data capture workflows with enterprise-grade mobile scanning,” said Samuel Mueller, CEO of Scandit. “We are delighted to play a part in this mobile evolution to help SAS meet its goals for outstanding customer service and operational efficiency.”
Resources
- View the SAS case study: https://www.scandit.com/resources/case-studies/sas/
- Learn more about Scandit’s air travel solutions: https://www.scandit.com/industries/air-travel/
- Download Scandit’s report (Fly High, One Mobile Scan at a Time) to learn how to innovate air travel with mobile computer vision and augmented reality: https://www.scandit.com/resources/whitepapers/fly-high-air-travel/
- Watch this video to see Scandit’s air travel solutions in action: https://www.scandit.com/resources/videos/air-travel-innovation-with-mobile-computer-vision/
- View Scandit’s press kit: https://www.scandit.com/press/
About Scandit
Scandit enables enterprises and consumers to change the way they interact with everyday objects and augment the physical world with real-time data captured by scanning barcodes and recognizing text, objects, and other visual identifiers using smartphones, tablets, wearables, drones, and robots.
Scandit’s mobile data capture platform is built on proprietary computer vision, augmented reality, and machine learning technologies. Companies in industries such as retail, transportation and logistics, manufacturing, and healthcare can use Scandit’s technology to create and power mobile apps for crucial enterprise workflows like search and find, shipping and receiving, inventory management, and proof of delivery.
Many of the world’s most innovative and successful companies are benefiting from Scandit’s enterprise-grade mobile data capture platform, including Alaska Airlines, FedEx, DHL, and PostNL.
For more information, visit https://www.scandit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191208005011/en/
Contact information
Brandon Watts
404-202-3476
brandon@wattsware.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom